Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis

The rare and heterogeneous kidney disorder C3 glomerulopathy (C3G) is characterized by dysregulation of the alternative pathway (AP) of the complement system. C3G is often associated with autoantibodies stabilizing the AP C3 convertase named C3 nephritic factors (C3NeF). The role of classical pathway (CP) convertase stabilization in C3G and related diseases such as immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) remains largely unknown. Here, we investigated the CP convertase activity in patients with C3G and IC-MPGN. Using a refined two-step hemolytic assay, we measured the stability of CP convertases directly in the serum of 52 patients and 17 healthy controls. In four patients, CP convertase activity was prolonged compared to healthy controls, i.e. the enzymatic complex was stabilized. In three patients (2 C3G, 1 IC-MPGN) the convertase stabilization was caused by immunoglobulins, indicating the presence of autoantibodies named C4 nephritic factors (C4NeFs). Importantly, the assay also enabled detection of non-immunoglobulin-mediated stabilization of the CP convertase in one patient with C3G. Prolonged CP convertase activity coincided with C3NeF activity in all patients and for up to 70 months of observation. Crucially, experiments with C3-depleted serum showed that C4NeFs stabilized the CP C3 convertase (C4bC2a), that does not contain C3NeF epitopes. All patients with prolonged CP convertase activity showed clear signs of complement activation, i.e. lowered C3 and C5 levels and elevated levels of C3d, C3bc, C3bBbP, and C5b-9. In conclusion, this work provides new insights into the diverse aspects and (non-)immunoglobulin nature of factors causing CP convertase overactivity in C3G/IC-MPGN.

[1]  E. Volokhina,et al.  Functional Hemolytic Test for Complement Alternative Pathway Convertase Activity. , 2021, Methods in molecular biology.

[2]  J. Wetzels,et al.  The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment , 2020, Cellular & Molecular Immunology.

[3]  S. Ołdziej,et al.  Gain-of-function mutation in complement C2 protein identified in patient with aHUS. , 2020, The Journal of allergy and clinical immunology.

[4]  K. Stirrups,et al.  Large-Scale Whole-Genome Sequencing Reveals the Genetic Architecture of Primary Membranoproliferative GN and C3 Glomerulopathy. , 2020, Journal of the American Society of Nephrology : JASN.

[5]  M. Rudnicki,et al.  Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis , 2019, Clinical kidney journal.

[6]  M. Rudnicki,et al.  C4 nephritic factor in patients with immune-complex-mediated membranoproliferative glomerulonephritis and C3-glomerulopathy , 2019, Orphanet Journal of Rare Diseases.

[7]  E. Volokhina,et al.  Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy , 2019, Front. Immunol..

[8]  F. Hildebrandt,et al.  Panel sequencing distinguishes monogenic forms of nephritis from nephrosis in children , 2019, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  G. Remuzzi,et al.  C3 glomerulopathy — understanding a rare complement-driven renal disease , 2019, Nature Reviews Nephrology.

[10]  C. Winkler,et al.  KIDNEY DISEASE IN THE SETTING OF HIV INFECTION: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE , 2018, Nephrology (Saint-Petersburg).

[11]  E. Volokhina,et al.  Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases , 2018, Front. Immunol..

[12]  G. Remuzzi,et al.  Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. , 2017, Journal of the American Society of Nephrology : JASN.

[13]  John D Lambris,et al.  The renaissance of complement therapeutics , 2018, Nature Reviews Nephrology.

[14]  Richard J. H. Smith,et al.  C4 Nephritic Factors in C3 Glomerulopathy: A Case Series. , 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  G. Deschênes,et al.  Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. , 2017, Journal of the American Society of Nephrology : JASN.

[16]  G. Ardissino,et al.  Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. , 2017, Kidney international.

[17]  E. Volokhina,et al.  Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome , 2016, Pediatric Nephrology.

[18]  A. Blom,et al.  Testing the Activity of Complement Convertases in Serum/Plasma for Diagnosis of C4NeF-Mediated C3 Glomerulonephritis , 2016, Journal of Clinical Immunology.

[19]  G. Remuzzi,et al.  Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. , 2016, Molecular immunology.

[20]  C. Licht,et al.  C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum , 2016, Pediatric Nephrology.

[21]  J. Wetzels,et al.  Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. , 2015, Clinical immunology.

[22]  V. Frémeaux-Bacchi,et al.  Complement System Part I – Molecular Mechanisms of Activation and Regulation , 2015, Front. Immunol..

[23]  J. Grünfeld,et al.  Heterogeneous histologic and clinical evolution in 3 cases of dense deposit disease with long-term follow-up. , 2014, Human pathology.

[24]  E. Volokhina,et al.  A novel method for direct measurement of complement convertases activity in human serum , 2014, Clinical and experimental immunology.

[25]  Bo Nilsson,et al.  An international serum standard for application in assays to detect human complement activation products. , 2013, Molecular immunology.

[26]  V. D’Agati,et al.  C3 glomerulopathy: consensus report , 2013, Kidney international.

[27]  S. Nasr,et al.  Atypical post-infectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement , 2012, Kidney international.

[28]  P. Densen,et al.  Autoantibody stabilization of the classical pathway C3 convertase leading to C3 deficiency and Neisserial sepsis: C4 nephritic factor revisited. , 2012, Clinical immunology.

[29]  A. Blom,et al.  Functional Analyses of Complement Convertases Using C3 and C5-Depleted Sera , 2012, PloS one.

[30]  J. Grünfeld,et al.  Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. , 2012, Kidney international.

[31]  S. Nasr,et al.  C3 Glomerulonephritis: Clinicopathologic findings, complement abnormalities, glomerular proteomic profile, treatment and follow-up , 2012, Kidney international.

[32]  T. Aitman,et al.  Acute Presentation and Persistent Glomerulonephritis Following Streptococcal Infection in a Patient With Heterozygous Complement Factor H–Related Protein 5 Deficiency , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  L. Katz,et al.  Causes of alternative pathway dysregulation in dense deposit disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[34]  John D Lambris,et al.  Complement: a key system for immune surveillance and homeostasis , 2010, Nature Immunology.

[35]  V. Frémeaux-Bacchi,et al.  C3 glomerulopathy: a new classification , 2010, Nature Reviews Nephrology.

[36]  B. Preston,et al.  Case Series , 2010, Toxicologic pathology.

[37]  M. Harboe,et al.  The alternative complement pathway revisited , 2008, Journal of cellular and molecular medicine.

[38]  H. Ohi,et al.  Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN) , 1994, Clinical and experimental immunology.

[39]  M. Hatano,et al.  C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis. , 1989, Clinical and experimental immunology.

[40]  I A Mjör,et al.  Consensus Report , 1985, Journal of dental research.

[41]  M. Daha,et al.  Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus. , 1984, Clinical and Experimental Immunology.

[42]  M. Kazatchkine,et al.  Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor , 1984, European journal of immunology.

[43]  M. Arakawa,et al.  Nephritic factor (NeF) of alternate pathway (NeFA) and of classical pathway (NeFc). , 1982, The Tohoku journal of experimental medicine.

[44]  I. Gigli,et al.  Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase , 1981, The Journal of experimental medicine.

[45]  M. Daha,et al.  Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. , 1980, Journal of immunology.

[46]  A. Cats,et al.  Stabilization of the classical pathway C3 convertase C42, by a factor F-42, isolated from serum of patients with systemic lupus erythematosus. , 1980, Immunology.

[47]  P. Lesavre,et al.  Nephritic factor of the classical pathway of complement: immunoglobulin G autoantibody directed against the classical pathway C3 convetase enzyme. , 1980, The Journal of clinical investigation.

[48]  M. Eberhard,et al.  The genus Mansonella (syn. Tetrapetalonema): a new classification. , 1984, Annales de parasitologie humaine et comparee.